
In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the evolution, research and pearls for ablation procedures, and emerging considerations for histotripsy in the realm of interventional oncology.
A new drug developed by Eli Lilly for the prevention of osteoporosis has been approved by the Food and Drug Administration. The drug, called Evista (raloxifene hydrochloride), will compete with Merck's Fosamax treatment, as well as estrogen-replacement
A new drug developed by Eli Lilly for the prevention of osteoporosis has been approved by the Food and Drug Administration. The drug, called Evista (raloxifene hydrochloride), will compete with Merck's Fosamax treatment, as well as estrogen-replacement therapies such as Premarin from American Home Products.





